Summary
• Cardiovascular disease and in particular coronary heart disease (CHD) are major causes of mortality and low density lipoprotein-cholesterol is causally related to CHD.
• Risk prevention requires a global approach for patient management, including lifestyle and dietary changes for all.
• Pharmaceutical lipid-lowering therapy using statins and non-statin combinations significantly improves cardiovascular outcomes.
• Severe hypercholesterolaemia and familial forms require aggressive lipid-lowering therapy.
• New approaches with anti-PCSK9 antibodies enable more therapeutic goals to be achieved.
• Residual inflammatory assessment may help guide risk evaluation and become a therapeutic target.
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Why envisage intensive LDL-cholesterol lowering and inhibition of inflammation?
Some of the first epidemiological studies associating coronary heart disease (CHD) with baseline cardiovascular risk factor variables date back to the 1960s, prior to therapeutic and Mendelian studies [3] , and point at both systolic blood pressure and serum cho- The first interventional studies aiming at establishing a causal relationship between CHD and cardiovascular risk began to emerge in the 1970s. One example is the co-operative trial in the primary prevention of ischaemic heart disease using clofibrate published in 1978, which included 15 745 males aged 30 to 59 years and with high cholesterol levels [4] . Treatment with clofibrate (ethyl-chlorophenoxyisobutyrate) resulted in an overall decrease in cholesterol levels by 9% versus placebo. Furthermore, the percentage of males free from all major ischaemic heart disease or nonfatal MI was higher in the clofibrate treatment arm, albeit associated with an excess mortality rate. Although this excess death rate was later attributed to issues not related to the drug, at the time it did lead to widespread scepticism regarding the benefit of cholesterol reduction in the prevention of CHD. Controversy over the benefit of lowering cholesterol continued until the end of the 1980s as further studies on clofibrate and other lipid lowering drugs were published, and culminated with the results of a trial on the effect of partial ileal bypass surgery on CHD mortality and morbidity in patients with hypercholesterolaemia, which concluded that, in patients who had had an MI, this procedure resulted in sustained improvements in blood lipid levels while at the same time reducing subsequent morbidity due to CHD [5] . (table 2) .
Drug options for intensive LDL-cholesterol reduction and achieving therapeutic goals
How then to achieve intensive LDL-C lowering? Bile acid resins or sequestrants will not be further covered in this review, nor will fibrates or nicotinic acid. In 1971, the search for microbial metabolites that would inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase began, and in 1990 the first statin was dis- low-dose (10 mg) atorvastatin was associated with a 2.2% absolute risk reduction and a 22% RR reduction in major cardiovascular events, at the expense, however, of increased alanine transaminase (ALT) levels [19] . In these studies, LDL-C levels were reduced to approximately 1.8 mmol/l (70 mg/dl), and the linear association between event rates and LDL-C levels was maintained. 
Clinical history
• Patients with premature coronary artery disease (men aged <55 years, women aged <60 years) 2
• Patients with premature cerebral or peripheral vascular disease (men aged <55 years, women aged <60 years) 1
Physical examination
• Tendinous xanthomata 6
• Arcus cornealis before 45 years of age 4
LDL-cholesterol level (mmol/l)
• ≥8.5 8
• 6.5-8.4 5
• 5.0-6.4 3
• 4.0-4.9 1
Molecular genetic testing (DNA analysis)
• Causative mutation shown in the LDLR, APOB or PCSK9 genes 8
It took almost ten more years before a major trial was able to show that the addition of a substance that re- 
The role of inflammation in atherosclerosis
The concomitant activation of inflammatory cascades resulting from the infiltration of oxidised LDL into en- shown to lead to rapid remission of symptoms [48, 49] .
In the field of cardiovascular disease, the effect of reducing inflammation without affecting lipid levels was tested in the Canakinumab Anti-inflammatory Throm- elevated baseline hsCRP and non-elevated LDL-C treated with statins who achieve both low CRP and low LDL-C levels seem to benefit most from statin therapy [46, 47, 53] . In secondary prevention, it may eventually be beneficial to distinguish patients with a residual cholesterol risk from those with a residual inflammatory risk, as the latter may also become a separate therapeutic target. Statins, as opposed to PCSK9 inhibitors, have both lipid lowering and anti-inflammatory properties and will therefore probably remain an integral part of therapy in secondary prevention, at least in the short to medium term. A more comprehensive approach to risk assessment will, moreover, be necessary in order to achieve a more personalised approach to patient management, integrating parameters such as genetic profiling, a complete lipid screening panel including Lp(a) and perhaps multiple hsCRP measurements to clearly evaluate the potential inflammatory risk.
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